Page 120 - Read Online

Muñoz-Martínez et al. Hepatoma Res 2022;8:30 https://dx.doi.org/10.20517/2394-5079.2022.22 Page 9 of 11

Availability of data and materials
Not applicable.

Financial support and sponsorship
María Londoño is funded by the Instituto de Salud Carlos III (grant No PI17/00955 and PI21/00080); André
s Cárdenas is funded by the Instituto de Salud Carlos III and Plan Estatal de Investigación Ciéntifica y Té
cnica y de Innovación - Grant No PI19/00752 and has received funding for this work by “Fundación Marta
Balust”. Alejandro Forner is funded by the Instituto de Salud Carlos III (grant No PI18/00542).

Conflicts of interest
Muñoz-Martínez S: speaker fees from Bayer and travel funding from Bayer and Eisai. He received grant
support from Bristol Myers Squibb and Celgene. Rimola J: has received speaker fees and travel grants from
Bayer, BTG and Terumo, and consultancy fees from Roche and COR2ED. Londoño MC: Lecture fees from
Intercept, Cárdenas A: is a consultant for Mallinckrodt Pharmaceuticals, Boston Scientific Corp, and has
participated on Advisory Boards for Mallinckrodt Pharmaceuticals, and has received grant support by
Mallinckrodt and Boston Scientific Corp. Forner A: lecture fees from Bayer, Gilead, Roche, Boston Scientific
and MSD; consultancy fees from Bayer, AstraZeneca, Roche, SIRTEX, AB Exact Science and Guerbert.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Written informed consent for publication was obtained (Figure 2).

Copyright
© The Author(s) 2022.

REFERENCES
1. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev
Gastroenterol Hepatol 2020;17:557-88. DOI PubMed PMC
2. Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. Nat Rev Dis Primers 2021;7:65. DOI PubMed PMC
3. Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of
cholangiocarcinoma. Liver Int 2019;39 Suppl 1:98-107. DOI PubMed
4. Izquierdo-Sanchez L, Lamarca A, La Casta A, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic
insights from the ENSCCA Registry. J Hepatol 2022;76:1109-21. DOI PubMed
5. Díaz-González Á, Forner A. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2016;30:1001-10. DOI
PubMed
6. Sherman M. How to improve HCC surveillance outcomes. JHEP Rep 2019;1:460-7. DOI PubMed PMC
7. Sherman M. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2014;28:783-93. DOI PubMed
8. Wilson JMG, Jungner G, Organization WH. Principles and practice of screening for disease. 1968.
9. Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ. Population-based screening for cancer: hope and hype. Nat Rev
Clin Oncol 2016;13:550-65. DOI PubMed PMC
10. Weismüller TJ, Trivedi PJ, Bergquist A, et al; International PSC Study Group. Patient Age, Sex, and Inflammatory Bowel Disease
Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology 2017;152:1975-1984.e8. DOI PubMed PMC
11. Fung BM, Tabibian JH. Cholangiocarcinoma in patients with primary sclerosing cholangitis. Curr Opin Gastroenterol 2020;36:77-84.
DOI PubMed
12. Boonstra K, Weersma RK, van Erpecum KJ, et al; EpiPSCPBC Study Group. Population-based epidemiology, malignancy risk, and
outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045-55. DOI
13. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing
cholangitis. Am J Gastroenterol 2004;99:523-6. DOI PubMed
14. Fevery J, Henckaerts L, Van Oirbeek R, et al. Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-
term single-centre study. Liver Int 2012;32:214-22. DOI PubMed
15. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic